# 5-Amino-1MQ Dosage and GLP-1 Stack Guide (With MOTS-C)
> Note: PeptIQ is not a medical provider. This article is for educational purposes only. Consult a qualified healthcare professional before starting any peptide or research compound protocol.
Answer first: 5-Amino-1MQ is an oral NNMT inhibitor, not an injectable peptide. Research-community dosing usually starts around 5–25mg/day (morning, often fasted), cycled roughly 8–12 weeks on / 4 weeks off. People stack it with GLP-1 agonists (appetite/energy expenditure) and MOTS-C (mitochondrial AMPK) because it targets a third lever: keeping visceral fat cells more metabolically active by blocking NNMT.
For solo dosing deep-dives, see the companion 5-Amino-1MQ dosing guide.
5-Amino-1MQ dose chart
| Use case | Oral dose discussed | Timing | Notes |
|---|---|---|---|
| Starter | 5mg/day | Morning, fasted or with NAD+ | Assess tolerance |
| Common research range | 10–25mg/day | Morning, pre-cardio or fasted | Most write-ups stay here |
| Exploratory high | 100–300mg+ | Same | Community experiments only; bioavailability ~40–50%; go slow with labs |
| Cycle framing | 8–12 weeks on | — | Often paired with ~4 weeks off |
Most compounds in the fat-loss space work through appetite suppression or increased energy expenditure. GLP-1 agonists like Retatrutide excel at the first. MOTS-C improves the second at the cellular level. 5-Amino-1MQ is the third lever.
What Is 5-Amino-1MQ?
5-Amino-1MQ (5-amino-1-methylquinolinium) is a selective inhibitor of NNMT — nicotinamide N-methyltransferase. That enzyme name sounds technical, but its role in fat metabolism is surprisingly straightforward once you understand it.
NNMT's job: Take nicotinamide (a NAD+ precursor) and methylate it — essentially tagging it for disposal. The more NNMT activity, the more your NAD+ precursors get converted into a form your cells can't use.
5-Amino-1MQ's job: Block NNMT. This does two things:
- Keeps NAD+ precursors available for actual NAD+ synthesis
- Depletes the methyl groups that fat cells use to maintain their metabolic "off" state
The second effect is the more interesting one. White adipose tissue — particularly visceral fat — uses a high-NNMT/low-NAD+ state to stay metabolically dormant. When NNMT is blocked, these fat cells shift toward a more metabolically active phenotype. In animal models, this translated to meaningful reductions in fat mass without changes in food intake.
The Research Behind It
The foundational work on 5-Amino-1MQ came from the Yoon lab at the University of Texas. In obese mouse models:
- Animals treated with 5-Amino-1MQ lost significant fat mass compared to controls
- Effects were most pronounced in visceral adipose tissue — the metabolically dangerous fat around organs
- No cardiovascular toxicity or significant off-target effects were observed at research doses
- Body weight decreased without appetite changes, suggesting the mechanism was purely metabolic
Human data is limited — this is still a research compound. But the mechanism is well-characterized and the target (NNMT in adipose tissue) is a legitimate pathway for visceral fat reduction.
Why It Pairs So Well With GLP-1 Agonists
GLP-1 agonists like Retatrutide create a caloric deficit through multiple routes: appetite suppression, slowed gastric emptying, and (in Reta's case) glucagon receptor agonism that drives additional energy expenditure. You're eating less and burning more.
The problem with prolonged caloric deficit is that metabolic adaptation — your body downregulates energy expenditure over time to resist the deficit.
5-Amino-1MQ addresses a specific piece of that adaptation: the fat cell's tendency to become increasingly metabolically dormant as weight loss continues. By blocking NNMT, you're keeping visceral fat cells in a more reactive state even as overall caloric restriction continues.
Practical result: Better visceral fat targeting during GLP-1 protocols, particularly in the later phases when the easy fat has already come off.
The MOTS-C Connection
MOTS-C activates AMPK through a mitochondrial stress pathway, improving fat oxidation and cellular energy efficiency. One of MOTS-C's downstream effects is increasing intracellular NAD+ utilization — the mitochondria are running harder, so they're consuming more of the NAD+ pool.
5-Amino-1MQ complements this by ensuring that pool stays replenished. NNMT normally burns through NAD+ precursors as a kind of metabolic "bleed." Block the bleed, and MOTS-C's expanded mitochondrial activity has more substrate to work with.
Some community members are running this sequence deliberately: start with NAD+ precursors (NMN/NR) to raise the baseline pool, then add MOTS-C to put that pool to work, then layer in 5-Amino-1MQ to block the pathway that drains it. The logic is solid, though it's worth noting this is a community-derived protocol, not a studied stack.
How to Dose 5-Amino-1MQ
5-Amino-1MQ is an oral compound. It is not a peptide, and there is no injectable form with established safety data — oral is the right route.
Standard research dose: 5–25mg/day oral
